Showing 1179 results
- https://www.novartis.com/news/media-releases/novartis-announces-study-nejm-showing-jakavi-was-superior-standard-therapy-rare-blood-cancer-polycythemia-veraJakavi® (ruxolitinib) treatment resulted in durable hematocrit control, spleen size reduction and symptom relief for patients with uncontrolled polycythemia vera[1] Polycythemia vera (PV) is…
- https://www.novartis.com/news/media-releases/novartis-delivered-solid-sales-growth-margin-expansion-and-pipeline-progress-2014-portfolio-transformation-will-focus-company-leading-businessesNet sales grew in FY 2014, with strong core[1] margin expansion Net sales increased 1% (+3% cc[1])[2] to USD 58.0 billion in FY (Q4: -2%, +4% cc) Operating income grew 1% (+7% cc) to USD 10.7…
- https://www.novartis.com/news/media-releases/novartis-erzielt-im-zweiten-quartal-eine-solide-performance-mit-starken-innovationen-und-fortschritten-bei-neueinfuhrungenDie fortzuführenden Geschäftsbereiche[2] steigern im zweiten Quartal den Umsatz, das operative Kernergebnis[1] und den Kerngewinn pro Aktie (kWk[1]): Der Nettoumsatz beläuft sich auf USD 12,7…
- https://www.novartis.com/news/media-releases/novartis-malaria-treatment-coartem-80480mg-receives-who-prequalification-enabling-greater-access-patientsWHO prequalified Coartem® 80/480mg is the first and only high strength malaria treatment available for donor-funded public sector procurement Coartem® 80/480mg reduces the pill burden for…
- https://www.novartis.com/news/media-releases/novartis-new-heart-failure-medicine-lcz696-now-called-entrestotm-approved-fda-reduce-risk-cardiovascular-death-and-heart-failure-hospitalizationFirst in the world approval brings hope of longer life and fewer hospitalizations for millions of Americans with heart failure with reduced ejection fraction Entresto is the first and only treatment…
- https://www.novartis.com/news/media-releases/alcon-receives-european-approval-pre-loaded-intraocular-lens-delivery-system-treat-patients-undergoing-cataract-surgeryAcrySof® IQ Aspheric Intraocular Lens (IOL) with UltraSertTM Pre-loaded Delivery System helps to maintain the integrity of the incision while facilitating smooth, consistent delivery of the IOL…
- https://www.novartis.com/news/media-releases/novartis-pharmaceuticals-launches-first-app-visually-impaired-people-use-apple-watch-and-other-smart-watchesNew features of the ViaOpta apps, previously available for iPhone and AndroidTM mobile phones, are also available to enhance the daily lives of people with visual impairments These apps…
- https://www.novartis.com/news/media-releases/novartis-deepens-its-industry-leading-pipeline-acquisition-spinifex-pharmaceuticals-incAcquisition adds novel angiotensin II Type 2 receptor antagonist for the treatment of neuropathic pain to Novartis' industry-leading development pipeline Neuropathic pain is a chronic…
- https://www.novartis.com/news/media-releases/novartis-announces-publication-lancet-showing-sustained-efficacy-secukinumab-over-one-year-psoriatic-arthritis-patientsIn the FUTURE 2 study, secukinumab demonstrated rapid onset of action, was significantly superior to placebo in improving signs and symptoms of psoriatic arthritis (PsA), with efficacy sustained…
- https://www.novartis.com/news/media-releases/novartis-drug-farydak-recommended-chmp-eu-approval-treat-multiple-myeloma-providing-patients-new-mechanism-actionFarydak (panobinostat) combination improved PFS by 7.8 months for patients who received >=2 prior regimens including bortezomib and an IMiD[1] Farydak would be the first HDAC inhibitor with…
Pagination
- ‹ Previous page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- …
- 118
- › Next page